N
Nicolas D. Iadarola
Researcher at National Institutes of Health
Publications - 4
Citations - 271
Nicolas D. Iadarola is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Antidepressant & Major depressive disorder. The author has an hindex of 4, co-authored 4 publications receiving 222 citations.
Papers
More filters
Journal ArticleDOI
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
Nicolas D. Iadarola,Mark J. Niciu,Erica M. Richards,Jennifer L. Vande Voort,Elizabeth D. Ballard,Nancy B. Lundin,Allison C. Nugent,Rodrigo Machado-Vieira,Carlos A. Zarate +8 more
TL;DR: Current efforts are focused on extending ketamine’s antidepressant efficacy, uncovering the neurobiological mechanisms responsible for ketamine's antidepressant activity in biologically enriched subgroups, and identifying treatment response biomarkers to personalize antidepressant selection.
Journal ArticleDOI
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
Brittany A. Jaso,Mark J. Niciu,Nicolas D. Iadarola,Níall Lally,Erica M. Richards,Minkyung Park,Elizabeth D. Ballard,Allison C. Nugent,Rodrigo Machado-Vieira,Carlos A. Zarate +9 more
TL;DR: Clinical evidence supporting the use of glutamate receptor modulators with direct affinity for cognate receptors is reviewed, including non-competitive NMDA receptor antagonists (ketamine, memantine, dextromethorphan, AZD6765), and theoretical glutamate receptor targets with preclinical antidepressant-like efficacy.
Journal ArticleDOI
The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder
Mark J. Niciu,Nicolas D. Iadarola,Dipavo Banerjee,David A. Luckenbaugh,Minkyung Park,Marc S. Lener,Lawrence Park,Dawn F. Ionescu,Elizabeth D. Ballard,Nancy E. Brutsche,Nirmala Akula,Francis J. McMahon,Rodrigo Machado-Vieira,Allison C. Nugent,Carlos A. Zarate +14 more
TL;DR: Baseline subcortical volumes implicated in MDD did not correlate with ketamine’s antidepressant efficacy, and baseline thalamic volume and BDNF genotype may be a combinatorial rapid antidepressant response biomarker.
Journal ArticleDOI
Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health
TL;DR: In general, research participation at the NIMH was not detrimental to health and safety, and conferred benefit in many cases, and this finding was true not only in the entire research population, but also in treatment-resistant subgroups and subgroups with a history of suicidality.